Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and ...

as we both anticipate Phase 3 PROSERA Study results in PAH and commence our PH-ILD Phase 3 study,” said Faheem Hasnain, Co-Founder, CEO, and Chairman of Gossamer Bio. “Proper clinical trial ...

Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Gossamer Bio (GOSS – Research Report). The associated ...

The company was founded by Faheem Hasnain and Sheila Gujrathi in 2015 and is headquartered in San Diego, CA. Read More on GOSS: Gossamer Bio NewsMORE Related Stocks Indices ...

"Looking forward, we expect 2025 to be an exceptionally important year for Gossamer, as we both anticipate Phase 3 PROSERA Study results in PAH and commence our PH-ILD Phase 3 study," said Faheem ...

The company was founded by Faheem Hasnain and Sheila Gujrathi in 2015 and is headquartered in San Diego, CA. Read More on GOSS: Gossamer Bio NewsMORE Related Stocks Indices Commodities ...

A look at the pros and cons of this popular income strategy. We sell different types of products and services to both investment professionals and individual investors. These products and services ...